José Alexandre Marzagão Barbuto

CONTACT

Lead Sponsor

University of Sao Paulo General Hospital

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Adult patients with a histological diagnosis of glioblastoma and confirmed IDH status.
•Currently undergoing standard-of-care treatment, which includes surgery, chemotherapy, and radiotherapy.
•Availability of pre-treatment magnetic resonance imaging (MRI).
•Ability to attend clinical follow-ups every 2 months.
•Functional performance score \> 50 at the time of study enrollment.
•Tumor cells capable of expansion in culture.

•Patients with any concomitant neoplasm (except basal cell carcinoma).
•Pregnant or breastfeeding individuals.
•Patients with significant medical or surgical conditions as determined by the study team, psychiatric disorders, or those requiring medications or treatments that could interfere with study procedures or the evaluation of the vaccine's safety and efficacy.
•Patients who are HIV-positive, immunosuppressed, and/or have undergone organ transplantation.
•Refusal or inability to provide consent, such as patients with aphasia.
•Participation in any experimental treatment protocols within the 6 months prior to enrollment.

Related studies

NCT06039709 · Recurrent Glioblastoma, Glioblastoma Multiforme, and more

NCT05765812 · Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III

NCT06814496 · Melanoma, Medullary Thyroid Cancer, and more

NCT06069726 · Recurrent Glioblastoma

NCT05969860 · Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, and more

Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma